Lineage Cell Therapeutics Stock Price - LCTX

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Lineage Cell Therapeutics Inc LCTX AMEX Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.12 -10.53% 1.02 1.15 1.00 1.14 1.14 15:36:42
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,007 965,432 $ 1.07 $ 1,031,787 1,027,224 0.5339 - 1.19
Last Trade Time Type Quantity Stock Price Currency
15:36:42 9,000 $ 1.02 USD

Lineage Cell Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 458.42M 449.38M -0.36 - 435.01M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
6.17M $ - 0.00% - -

more financials information »

Lineage Cell Therapeutics News

Loading Messages....

Latest LCTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical LCTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.851.190.791.061,817,8430.1720.0%
1 Month0.91981.190.7294410.9411242948,1230.100210.89%
3 Months0.84391.190.53390.818911895,8720.176120.87%
6 Months0.95951.190.53390.8603667621,1780.06056.31%
1 Year0.95951.190.53390.8603667621,1780.06056.31%
3 Years0.95951.190.53390.8603667621,1780.06056.31%
5 Years0.95951.190.53390.8603667621,1780.06056.31%

Lineage Cell Therapeutics Description

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. BioTime's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.

Your Recent History
Lineage Ce..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.